The role of statins in breast cancer survivors.

IF 3 3区医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2025-02-01 Epub Date: 2025-01-16 DOI:10.1007/s10549-024-07605-2

Saffiya Z Bashey, Avram Kordon, Kamari Ositelu, Anjali Rao, Nausheen Akhter

{"title":"The role of statins in breast cancer survivors.","authors":"Saffiya Z Bashey, Avram Kordon, Kamari Ositelu, Anjali Rao, Nausheen Akhter","doi":"10.1007/s10549-024-07605-2","DOIUrl":null,"url":null,"abstract":"Purpose: As breast cancer survival rates improve, cardiovascular disease (CVD) has become a critical concern among survivors due to co-morbidities and the cardiotoxic effects of cancer treatments. The risk of developing CVD in this population may surpass the risk of cancer recurrence. This review aims to analyze existing research on the use of statins in breast cancer survivors, focusing on their potential role in mitigating cardiovascular risk and cancer recurrence.Methods: The review begins by exploring the shared mechanisms underlying the development of both heart disease and breast cancer. It then examines the evidence for the role of statins in reducing cancer therapy-related cardiac dysfunction (CTRCD) and breast cancer recurrence, highlighting findings from the literature on their anti-inflammatory and lipid-lowering effects.Results: The analysis reveals that statins may offer benefits beyond their traditional cardiovascular applications. Evidence suggests that statins could reduce the risk of CTRCD and potentially lower the risk of breast cancer recurrence.Conclusions: Statins demonstrate promising potential in providing dual benefits for breast cancer survivors by mitigating CVD risk and possibly reducing the likelihood of cancer recurrence. However, additional studies are required to better understand the specific role of statins in breast cancer prevention and survivorship care.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"1-10"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07605-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: As breast cancer survival rates improve, cardiovascular disease (CVD) has become a critical concern among survivors due to co-morbidities and the cardiotoxic effects of cancer treatments. The risk of developing CVD in this population may surpass the risk of cancer recurrence. This review aims to analyze existing research on the use of statins in breast cancer survivors, focusing on their potential role in mitigating cardiovascular risk and cancer recurrence.

Methods: The review begins by exploring the shared mechanisms underlying the development of both heart disease and breast cancer. It then examines the evidence for the role of statins in reducing cancer therapy-related cardiac dysfunction (CTRCD) and breast cancer recurrence, highlighting findings from the literature on their anti-inflammatory and lipid-lowering effects.

Results: The analysis reveals that statins may offer benefits beyond their traditional cardiovascular applications. Evidence suggests that statins could reduce the risk of CTRCD and potentially lower the risk of breast cancer recurrence.

Conclusions: Statins demonstrate promising potential in providing dual benefits for breast cancer survivors by mitigating CVD risk and possibly reducing the likelihood of cancer recurrence. However, additional studies are required to better understand the specific role of statins in breast cancer prevention and survivorship care.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他汀类药物在乳腺癌幸存者中的作用。

目的：随着乳腺癌生存率的提高，由于癌症治疗的合并症和心脏毒性作用，心血管疾病（CVD）已成为幸存者关注的关键问题。在这一人群中，患心血管疾病的风险可能超过癌症复发的风险。本综述旨在分析他汀类药物在乳腺癌幸存者中使用的现有研究，重点关注其在降低心血管风险和癌症复发方面的潜在作用。方法：综述从探讨心脏病和乳腺癌发展的共同机制开始。然后研究了他汀类药物在减少癌症治疗相关心功能障碍（CTRCD）和乳腺癌复发方面的作用的证据，强调了文献中关于其抗炎和降脂作用的发现。结果：分析显示他汀类药物可能提供超出其传统心血管应用的益处。有证据表明，他汀类药物可以降低CTRCD的风险，并可能降低乳腺癌复发的风险。结论：他汀类药物通过降低心血管疾病风险和可能降低癌症复发的可能性，为乳腺癌幸存者提供了良好的双重益处。然而，需要更多的研究来更好地了解他汀类药物在乳腺癌预防和生存护理中的具体作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.